Story perspectives

Eli Lilly Urges Recall of Risky Compounded Tirzepatide

3/13/2026

Summary

Story summary

Eli Lilly warns that compounded tirzepatide mixed with vitamin B12 contains an impurity with unknown health effects.
The company says these compounded products lack rigorous testing and Food and Drug Administration (FDA) approval, creating safety concerns for patients.
Lilly is calling for a nationwide recall of the compounded products and criticizes mass compounding as risky.
Compounding pharmacies are not subject to the same reporting standards as FDA-approved manufacturers, raising additional safety concerns.

1 of 1

Story summary

Eli Lilly warns that compounded tirzepatide mixed with vitamin B12 contains an impurity with unknown health effects.
The company says these compounded products lack rigorous testing and Food and Drug Administration (FDA) approval, creating safety concerns for patients.
Lilly is calling for a nationwide recall of the compounded products and criticizes mass compounding as risky.
Compounding pharmacies are not subject to the same reporting standards as FDA-approved manufacturers, raising additional safety concerns.